Abstract
Background: Prostate cancer is one of the most commonly diagnosed cancers and one of the most common causes of cancer-related deaths among men worldwide. Patients who are diagnosed with localized prostate cancer and treated with radical prostatectomy often respond well to therapy. The current standard therapy for prostate cancer involves maximal surgical resection, followed by radiotherapy and chemotherapy. Clarifying the molecular mechanism of tumor proliferation and recurrence becomes more and more important for clinical therapies of prostate cancer.
Methods: Quantitative Real-Time PCR and Western-blot were used in the detection of mRNA and protein expression. Lentivirus infection was used to overexpress or knockdown the target gene. Flow cytometry analysis was performed to test protein expression and apoptosis level. Immunohistochemistry was used to identify protein expression in tissue. Statistical differences between the two groups are evaluated by two-tailed t-tests. The comparison among multiple groups is performed by one-way Analysis of Variance (ANOVA) followed by Dunnett’s posttest. The statistical significance of the Kaplan-Meier survival plot is determined by log-rank analysis.
Results: In this study, we identified that FOXM1 expression was significantly enriched in prostate cancer compared with normal tissue. Additionally, FOXM1 was functionally required for tumor proliferation and its expression was associated with poor prognosis in prostate cancer patients. Mechanically, FOXM1-dependent regulation of EZH2 is essential for proliferation and progression in prostate cancer.
Conclusion: Taken together, our data suggest that oncogenic transcription factor FoxM1 is up-regulated in prostate cancer, suggesting that the growth of cancer cells may depend on FOXM1 activity. FOXM1 may serve as a clinical prognostic factor and a therapeutic target for prostate cancer.
Keywords: FOXM1, EZH2, prostate cancer, proliferation, transcription, cancer therapy.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer
Volume: 21 Issue: 14
Author(s): Juan-Hua Tian, Li-Jun Mu, Mei-Yu Wang, Jin Zeng, Qing-Zhi Long, Bin-Guan, Wen Wang, Yu-Mei Jiang, Xiao-Jing Bai and Yue-Feng Du*
Affiliation:
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061,China
Keywords: FOXM1, EZH2, prostate cancer, proliferation, transcription, cancer therapy.
Abstract:
Background: Prostate cancer is one of the most commonly diagnosed cancers and one of the most common causes of cancer-related deaths among men worldwide. Patients who are diagnosed with localized prostate cancer and treated with radical prostatectomy often respond well to therapy. The current standard therapy for prostate cancer involves maximal surgical resection, followed by radiotherapy and chemotherapy. Clarifying the molecular mechanism of tumor proliferation and recurrence becomes more and more important for clinical therapies of prostate cancer.
Methods: Quantitative Real-Time PCR and Western-blot were used in the detection of mRNA and protein expression. Lentivirus infection was used to overexpress or knockdown the target gene. Flow cytometry analysis was performed to test protein expression and apoptosis level. Immunohistochemistry was used to identify protein expression in tissue. Statistical differences between the two groups are evaluated by two-tailed t-tests. The comparison among multiple groups is performed by one-way Analysis of Variance (ANOVA) followed by Dunnett’s posttest. The statistical significance of the Kaplan-Meier survival plot is determined by log-rank analysis.
Results: In this study, we identified that FOXM1 expression was significantly enriched in prostate cancer compared with normal tissue. Additionally, FOXM1 was functionally required for tumor proliferation and its expression was associated with poor prognosis in prostate cancer patients. Mechanically, FOXM1-dependent regulation of EZH2 is essential for proliferation and progression in prostate cancer.
Conclusion: Taken together, our data suggest that oncogenic transcription factor FoxM1 is up-regulated in prostate cancer, suggesting that the growth of cancer cells may depend on FOXM1 activity. FOXM1 may serve as a clinical prognostic factor and a therapeutic target for prostate cancer.
Export Options
About this article
Cite this article as:
Tian Juan-Hua , Mu Li-Jun , Wang Mei-Yu , Zeng Jin , Long Qing-Zhi , Bin-Guan , Wang Wen, Jiang Yu-Mei, Bai Xiao-Jing and Du Yue-Feng *, FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer, Anti-Cancer Agents in Medicinal Chemistry 2021; 21 (14) . https://dx.doi.org/10.2174/1871520620666200731161810
DOI https://dx.doi.org/10.2174/1871520620666200731161810 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets TGF Beta Inhibition for Cancer Therapy
Current Cancer Drug Targets The Role of Apoptosis in Tumor Progression and Metastasis
Current Molecular Medicine Sympathetic Signaling in Angiogenesis: Implications for Cancer Progression
Current Cancer Therapy Reviews Synthesis, <i>In Silico</i> and <i>In Vivo</i> Evaluation of Novel 1, 3, 4-Thiadiazole Analogues as Novel Anticancer Agents
Letters in Drug Design & Discovery Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Anticancer Advances of Matrine and Its Derivatives
Current Pharmaceutical Design The Proteins of Plant Defensin Family and their Application Beyond Plant Disease Control
Recent Patents on DNA & Gene Sequences The Impact of Thrombopoietin on Clinical Practice
Current Pharmaceutical Design Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Topics of Physiological and Pathophysiological Functions of Lymphatics
Current Molecular Medicine Receptor Proteins for Nongenomic Actions of Thyroid Hormone
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Heat Shock Proteins in Cancer: Signaling Pathways, Tumor Markers and Molecular Targets in Liver Malignancy
Protein & Peptide Letters Synthesis and Antitumor Invasive Activity of Novel Ionone Alkaloid Derivatives
Letters in Drug Design & Discovery Exploiting Significance of Physical Exercise in Prevention of Gastrointestinal Disorders
Current Pharmaceutical Design A Critical Review on Potential Advancements of Nanostructured Lipid Carriers in Drug Delivery
Current Nanomedicine Nanocarriers for Gene Delivery - Polymer Structure, Targeting Ligands and Controlled-Release Devices
Current Nanoscience Advances in the use of MOFs for Cancer Diagnosis and Treatment: An Overview
Current Pharmaceutical Design The Biphasic Expression Pattern of miR-200a and E-cadherin in Epithelial Ovarian Cancer and its Correlation with Clinicopathological Features
Current Pharmaceutical Design Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
Current Molecular Medicine